Related Experiment Videos
Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1
1Laboratory of Molecular Immunoregulation, Division of Basic Sciences, International Corporation Frederick, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland 21702, USA.
Abstract:
Amyloid beta (Abeta) is a major contributor to the pathogenesis of Alzheimer's disease (AD). Although Abeta has been reported to be directly neurotoxic, it also causes indirect neuronal damage by activating mononuclear phagocytes (microglia) that accumulate in and around senile plaques. In this study, we show that the 42 amino acid form of beta amyloid peptide, Abeta(42), is a chemotactic agonist for a seven-transmembrane, G-protein-coupled receptor named FPR-Like-1 (FPRL1), which is expressed on human mononuclear phagocytes. Moreover, FPRL1 is expressed at high levels by inflammatory cells infiltrating senile plaques in brain tissues from AD patients. Thus, FPRL1 may mediate inflammation seen in AD and is a potential target for developing therapeutic agents.
Insights
Alzheimer's disease involves amyloid beta (Abeta). This study reveals Abeta(42) activates FPR-Like-1 (FPRL1) on immune cells, suggesting FPRL1 as a therapeutic target for AD-related inflammation.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Amyloid beta (Abeta) is implicated in Alzheimer's disease (AD) pathogenesis.
- Abeta causes neurotoxicity directly and indirectly via immune cell activation.
- Microglia activation and accumulation in senile plaques contribute to neuronal damage.
Purpose of the Study:
- To investigate the interaction between Abeta and mononuclear phagocytes.
- To identify receptors mediating Abeta-induced inflammation in AD.
- To explore potential therapeutic targets for Alzheimer's disease.
Main Methods:
- Characterization of Abeta(42) as a ligand.
- Analysis of FPR-Like-1 (FPRL1) expression on human mononuclear phagocytes.
- Examination of FPRL1 expression in brain tissues from AD patients.
Main Results:
- Abeta(42) functions as a chemotactic agonist for FPRL1.
- FPRL1 is expressed on human mononuclear phagocytes.
- High levels of FPRL1 are found on inflammatory cells within senile plaques in AD brains.
Conclusions:
- FPRL1 mediates Abeta-induced inflammation in Alzheimer's disease.
- FPRL1 is a potential therapeutic target for AD.
- Targeting FPRL1 may offer a novel strategy for treating AD-related neuroinflammation.